FDA Approval Summary: Ruxolitinib for Treatment of Steroid‐Refractory Acute Graft‐Versus‐Host Disease

On May 24, 2019, the Food and Drug Administration approved ruxolitinib for steroid‐refractory acute graft‐versus‐host disease (SR‐aGVHD) in adult and pediatric patients 12 years and older. Approval was based on Study INCB 18424‐271 (REACH‐1; NCT02953678), an open‐label, single‐arm, multicenter trial...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Przepiorka, Donna, Luo, Lola, Subramaniam, Sriram, Qiu, Junshan, Gudi, Ramadevi, Cunningham, Lea C., Nie, Lei, Leong, Ruby, Ma, Lian, Sheth, Christopher, Deisseroth, Albert, Goldberg, Kirsten B., Blumenthal, Gideon M., Pazdur, Richard
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2019
Assuntos:
Regulatory Issues: FDA
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7011641/
https://ncbi.nlm.nih.gov/pubmed/32043777
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0627
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados